Ardelyx reported $31.21M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Amgen USD 13.99B 1.95B Jun/2026
Ardelyx USD 31.21M 36.79M Mar/2026
aTyr Pharma USD 16.16M 6.15M Jun/2026
Corcept Therapeutics USD 111.04M 2.3M Jun/2026
Curis USD 10.14M 10.14M Jun/2025
Sanofi EUR 5.54B 2.11B Mar/2026
TG Therapeutics USD 612.25M 170.04M Jun/2026
United Therapeutics USD 1.8B 523.5M Jun/2026